Krystal Biotech vs Roivant Sciences
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Krystal Biotech and Roivant Sciences side by side, using each oneβs latest annual report. Here is what stands out:
- Krystal Biotech is the larger business, with $389M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 47 times as much.
- Krystal Biotech grew revenue faster (33.9%, against β71.6%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against β6,235.7%).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against β9,183.5%).
- Krystal Biotech earned a higher return on the capital invested in it (43.6%, against β62.6%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Krystal Biotech
KRYS
7/8
Revenue growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-score
Roivant Sciences
ROIV
1/8
Share count change
Side by side
Best in the row
| Latest fiscal year | KRYS FY25 | ROIV FY25 |
|---|---|---|
| Size | ||
| Market cap | $9.6B | $26.3B |
| Revenue | $389M | $8.3M |
| Free cash flow | $189M | β$759M |
| Net income | $205M | β$300M |
| Growth | ||
| Revenue growth | 33.9% | β71.6% |
| 5-year growth | β | β19.0% |
| Share count change | 0.7% | β4.4% |
| Profitability | ||
| Gross margin | β | β |
| Operating margin | 41.5% | β6,235.7% |
| Net margin | 52.6% | β3,629.2% |
| FCF margin | 48.6% | β9,183.5% |
| Return on capital | 43.6% | β62.6% |
| Return on equity | 18.9% | β6.5% |
| Balance sheet | ||
| Net debt | β$828M | β$4.3B |
| Net debt / EBITDA | β5.0x | β |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 39.0x | β |
| Piotroski F-score | 5 | 1 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.